Novavax shares are trading lower amid a pullback in the stock, which gained Tuesday after the FDA granted Emergency Use Authorization for the company's updated protein-based COVID-19 vaccine for people 12 and older.
Portfolio Pulse from Benzinga Newsdesk
Novavax shares are trading lower despite the FDA granting Emergency Use Authorization for the company's updated protein-based COVID-19 vaccine for people aged 12 and older. This comes after a recent gain in the stock.
October 04, 2023 | 5:38 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Novavax's stock is trading lower despite FDA's Emergency Use Authorization for its updated COVID-19 vaccine. This follows a recent increase in the stock price.
Despite the positive news of FDA's Emergency Use Authorization for Novavax's updated COVID-19 vaccine, the company's stock is trading lower. This could be due to a variety of factors, including market volatility or profit-taking after the recent gain in the stock. The news is highly relevant and important to Novavax as it directly pertains to one of their key products.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100